Get rich slowly
Results 1 - 10 of 1709 : 1 2 3 4 5 6 7 8 9 Next
How the Wheels Came off GlaxoSmithKline's Bus
Just the facts, Fool.
Is Avanir Pharmaceuticals the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
1 Cheap Biotech Small-Cap With Huge Potential
Several big-name partnerships and a lot of cash make this one attractive company.
Don't Bet Against This Biotech IPO
Verastem has good management.
Kidney cancer drug Inlyta is approved -- now comes the competition.
Has GlaxoSmithKline Become the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
19 Clinical Trials Aren't Enough
The FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin.
GlaxoSmithKline: Dividend Dynamo or Blowup?
What the numbers tell us.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK